Lung adenocarcinoma architecture predicts survival

March 8, 2012
Lung adenocarcinoma architecture predicts survival

(HealthDay) -- A new method of classifying invasive pulmonary adenocarcinomas, based on the predominant architecture developed by the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS), is a stage-independent predictor of survival, according to research published online March 5 in the Journal of Clinical Oncology.

To evaluate the prognostic impact of the new IASLC/ATS/ERS adenocarcinoma classification system, Arne Warth, M.D., of the University Hospital Heidelberg in Germany, and colleagues conducted a retrospective study utilizing data regarding the predominant architecture and histomorphology of resected adenocarcinomas from 500 patients.

The researchers found that the overall survival of patients with each type of adenocarcinoma architecture was significantly different: 78.5 months for lepidic, 67.3 for acinar, 58.1 for solid, 48.9 for papillary, and 44.9 for micropapillary. When the patterns were grouped, the differences were more pronounced: pattern groups 1, 2, and 3 had survival of 78.5, 67.3, and 57.2 months, respectively. Similar between-group differences were observed for patient disease-specific, disease-free, and overall survival. The prognostic value of these pattern groups was independent of adenocarcinoma stage and therapy used, but was influenced by adjuvant chemoradiotherapy. There was a close association between the predominant pattern and the risk of developing nodal metastases.

"Besides all recent molecular progress, architectural grading of pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS scheme is a rapid, straightforward, and efficient discriminator for and may support patient stratification for adjuvant chemoradiotherapy," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Lymphomas tied to metabolic disruption

July 17, 2015

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio have found evidence that directly links disrupted metabolism (energy production in cells) to a common and often fatal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.